Tag: Therapeutics
Phaxiam Therapeutics withdraws from Nasdaq – 02/21/2024 at 10:02
(AOF) – Phaxiam Therapeutics announced that it has officially notified Nasdaq of its intention to voluntarily delist its American Depositary Shares (“ADS”) representing its ordinary shares. The withdrawal should be…
PHAXIAM Therapeutics announces its cash level at the end of 2023 and its 2024 financial calendar – 01/18/2024 at 10:05 p.m.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email to the following address: [email protected] Lyon (France) and Cambridge (MA,…
Bone therapeutics: The partnership with Phebra PTY is evolving
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Roche: licensing agreement with Remix Therapeutics
(CercleFinance.com) – Remix Therapeutics announced on Wednesday the conclusion of a collaboration and licensing agreement with Roche relating to the development of small therapeutic molecules targeting RNA. In a statement,…
Bristol Myers buys Karuna Therapeutics and its schizophrenia treatment for $14 billion
Published on 12/22/2023 at 3:05 p.m. December 22 (Reuters) – Bristol Myers Squibb announced on Friday an agreement to acquire Karuna Therapeutics for $14 billion…
Run on Karuna Therapeutics: Wall Street is taking it easy before Christmas
Run on Karuna Therapeutics Wall Street is taking it easy before Christmas December 22, 2023, 11:18 p.m Listen to article This audio version was artificially generated. More info | Send…
Outlook Therapeutics reduces its losses in 2023 – 12/22/2023 at 2:45 p.m.
(AOF) – Outlook Therapeutics is expected to rise in pre-market on Wall Street after the publication of improving results. The annual loss per share stood at $0.24 compared to $0.31…
PHAXIAM Therapeutics provides an update on its activities and publishes its third quarter 2023 results – 11/14/2023 at 10:05 p.m.
Webinar in French on Wednesday November 15, 2023 at 11:00 a.m. CET Pursuit of an ambitious clinical development strategy to create a world leader in phage therapy targeting high value-added…
2023 – PHAXIAM Therapeutics obtains the necessary authorizations to launch its phase 1 study in infectious endocarditis caused by Staphylococcus aureus
Approval of the study protocol by the ANSM and the Committee for the Protection of People (CPP) Sud-Est II Lyon Start of recruitment of 12 patients planned during the 4th…
PHAXIAM Therapeutics obtains the necessary authorizations to launch its phase 1 study in infective endocarditis caused by Staphylococcus aureus – 10/24/2023 at 10:05 p.m.
Approval of the study protocol by the ANSM and the Committee for the Protection of People (CPP) Sud-Est II Lyon Start of recruitment of 12 patients planned during the 4th…
PHAXIAM Therapeutics obtains the necessary authorizations to launch its phase 1 study in infective endocarditis caused by Staphylococcus aureus – 10/24/2023 at 10:05 p.m.
Approval of the study protocol by the ANSM and the Committee for the Protection of People (CPP) Sud-Est II Lyon Start of recruitment of 12 patients planned for the 4th…
PHAXIAM Therapeutics announces a high level of performance of its two anti-Staphylococcus aureus phages on clinical strains – 10/09/2023 at 10:05 p.m.
Data obtained from the phagogram developed by PHAXIAM, the first phage sensitivity test with CE marking, showed a response rate of 98% on 105 clinical strains of S. aureus. Lyon…